Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy

Inclusion Criteria: * 1\. Sign an informed consent form; * 2\. HBsAg (+), and the course of the disease exceeds six months; * 3\. Age range from 16 to 70 years old; * 4\. Female participants of childbearing age who had a negative pregnancy test before the trial and were able to take effective contraceptive measures; * 5\. During the treatment period, within six months after the end of treatment, the patients agrees to use contraception Exclusion Criteria: * 1\. Patients with a known history of allergy to Peg-IFNα and NAs; * 2\. Co-infection with other virus such as HAV, HCV, HDV, HEV, HIV, etc; * 3\. Patients with liver cirrhosis or a Child Pugh score of 7 or above; * 4\. History or evidence of liver disease caused by other factors (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic fatty liver disease, drug-induced hepatitis, hepatolenticular degeneration, etc.); * 5\. Pregnant or lactating women; Have a history of alcohol or drug abuse within the year prior to the trial enrollment screening; * 6\. Neutrophil count\<1.5 × 109/L or hemoglobin\<100g/L or platelet count\<80 × 109/L; During the trial enrollment screening, serum creatinine was higher than the upper normal limit; * 7\. A history of severe diseases in important organs and tissues such as the heart, brain, kidneys, retina, and muscles; * 8\. Having a history of mental illness or a family history of mental illness, or a Hamilton Depression Scale score greater than 7 points; * 9\. History of endocrine system or autoimmune diseases, such as thyroid disease, diabetes, systemic lupus erythematosus, sarcoidosis, autoimmune thrombocytopenic purpura, etc; * 10\. History of malignant tumors; * 11\. During the trial enrollment screening, suspicious liver malignant tumors were detected by ultrasound, or AFP was greater than 100ng/mL or AFP cannot remain stable within 3 months prior to the experiment; * 12\. Has a history of important organ transplantation; * 13\. Other diseases that researchers believe are not suitable for inclusion.